Matthew T Sutherland1, Kimberly L Ray2, Michael C Riedel3, Julio A Yanes4, Elliot A Stein5, Angela R Laird4. 1. Department of Psychology, Florida International University, Miami, Florida. Electronic address: masuther@fiu.edu. 2. Department of Psychiatry, University of California, Davis, Sacramento, California. 3. Research Imaging Institute, University of Texas Health Science Center, San Antonio, Texas. 4. Department of Physics, Florida International University, Miami, Florida. 5. Neuroimaging Research Branch, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health/Department of Health and Human Services, Baltimore, Maryland.
Abstract
BACKGROUND: Nicotinic acetylcholine receptor (nAChR) agonists augment cognition among cigarette smokers and nonsmokers, yet the systems-level neurobiological mechanisms underlying such improvements are not fully understood. Aggregating neuroimaging results regarding nAChR agonists provides a means to identify common functional brain changes that may be related to procognitive drug effects. METHODS: We conducted a meta-analysis of pharmacologic neuroimaging studies within the activation likelihood estimation framework. We identified published studies contrasting a nAChR drug condition versus a baseline and coded each contrast by activity change direction (decrease or increase), participant characteristics (smokers or nonsmokers), and drug manipulation employed (pharmacologic administration or cigarette smoking). RESULTS: When considering all studies, nAChR agonist administration was associated with activity decreases in multiple regions, including the ventromedial prefrontal cortex (vmPFC), posterior cingulate cortex (PCC), parahippocampus, insula, and the parietal and precentral cortices. Conversely, activity increases were observed in lateral frontoparietal cortices, the anterior cingulate cortex, thalamus, and cuneus. Exploratory analyses indicated that both smokers and nonsmokers showed activity decreases in the vmPFC and PCC, and increases in lateral frontoparietal regions. Among smokers, both pharmacologic administration and cigarette smoking were associated with activity decreases in the vmPFC, PCC, and insula and increases in the lateral PFC, dorsal anterior cingulate cortex, thalamus, and cuneus. CONCLUSIONS: These results provide support for the systems-level perspective that nAChR agonists suppress activity in default-mode network regions and enhance activity in executive control network regions in addition to reducing activation of some task-related regions. We speculate these are potential mechanisms by which nAChR agonists enhance cognition.
BACKGROUND:Nicotinic acetylcholine receptor (nAChR) agonists augment cognition among cigarette smokers and nonsmokers, yet the systems-level neurobiological mechanisms underlying such improvements are not fully understood. Aggregating neuroimaging results regarding nAChR agonists provides a means to identify common functional brain changes that may be related to procognitive drug effects. METHODS: We conducted a meta-analysis of pharmacologic neuroimaging studies within the activation likelihood estimation framework. We identified published studies contrasting a nAChR drug condition versus a baseline and coded each contrast by activity change direction (decrease or increase), participant characteristics (smokers or nonsmokers), and drug manipulation employed (pharmacologic administration or cigarette smoking). RESULTS: When considering all studies, nAChR agonist administration was associated with activity decreases in multiple regions, including the ventromedial prefrontal cortex (vmPFC), posterior cingulate cortex (PCC), parahippocampus, insula, and the parietal and precentral cortices. Conversely, activity increases were observed in lateral frontoparietal cortices, the anterior cingulate cortex, thalamus, and cuneus. Exploratory analyses indicated that both smokers and nonsmokers showed activity decreases in the vmPFC and PCC, and increases in lateral frontoparietal regions. Among smokers, both pharmacologic administration and cigarette smoking were associated with activity decreases in the vmPFC, PCC, and insula and increases in the lateral PFC, dorsal anterior cingulate cortex, thalamus, and cuneus. CONCLUSIONS: These results provide support for the systems-level perspective that nAChR agonists suppress activity in default-mode network regions and enhance activity in executive control network regions in addition to reducing activation of some task-related regions. We speculate these are potential mechanisms by which nAChR agonists enhance cognition.
Authors: Britta Hahn; Thomas J Ross; Frank A Wolkenberg; Diaa M Shakleya; Marilyn A Huestis; Elliot A Stein Journal: Cereb Cortex Date: 2008-12-10 Impact factor: 5.357
Authors: Freda Patterson; Christopher Jepson; Andrew A Strasser; James Loughead; Kenneth A Perkins; Ruben C Gur; Joseph M Frey; Steven Siegel; Caryn Lerman Journal: Biol Psychiatry Date: 2008-10-08 Impact factor: 13.382
Authors: Amy C Janes; Maya Zegel; Kyoko Ohashi; Jennifer Betts; Elena Molokotos; David Olson; Lauren Moran; Diego A Pizzagalli Journal: Neuropsychopharmacology Date: 2018-04-19 Impact factor: 7.853
Authors: Peter M Thompson; Dianne A Cruz; Elizabeth A Fucich; Dianna Y Olukotun; Masami Takahashi; Makoto Itakura Journal: Mol Neuropsychiatry Date: 2015-12-01
Authors: Alicia M Allen; Andrea H Weinberger; Reagan R Wetherill; Carol L Howe; Sherry A McKee Journal: Nicotine Tob Res Date: 2019-04-17 Impact factor: 4.244
Authors: Bader Chaarani; Kees-Jan Kan; Scott Mackey; Philip A Spechler; Alexandra Potter; Catherine Orr; Nicholas D'Alberto; Kelsey E Hudson; Tobias Banaschewski; Arun L W Bokde; Uli Bromberg; Christian Büchel; Anna Cattrell; Patricia J Conrod; Sylvane Desrivières; Herta Flor; Vincent Frouin; Jürgen Gallinat; Penny Gowland; Andreas Heinz; Bernd Ittermann; Jean-Luc Martinot; Frauke Nees; Dimitri Papadopoulos-Orfanos; Tomáš Paus; Luise Poustka; Michael N Smolka; Henrik Walter; Robert Whelan; Stephen T Higgins; Gunter Schumann; Robert R Althoff; Elliot A Stein; Hugh Garavan Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2019-03-15